AN1 16.7% 1.4¢ anagenics limited

News: Cellmid's CEO Maria Halasz leads way with on-market purchase

  1. Cellmid's (ASX:CDY) chief executive officer Maria Halasz has increased her stake in the company through an on-market purchase of shares.

    Halasz purchased 370,000 for a consideration of $9,990, or around $0.027 a share. The stock closed at $0.028 on Friday.

    Halasz now holds a direct stake of over 1.55 million shares and 12 million (loan) shares, and an indirect stake of:

    - (Direct Capital Pty Ltd) of 5.8 million shares and 7 million unlisted options (20 Nov 2014 $0.056), 1.5 million listed options (23 Oct 2016 $0.034); and

    - (Direct Capital Group Pty Ltd) 3,515,625 shares and 5 million unlisted options (15 June 2017 $0.032).

    Earlier in the month Cellmid reported a 267% increase in total revenue to $2.8 million for the financial year ended 30 June 2014 with revenue from product sales rising more than 112% to $1.15 million.

    This follows the first full year of operations for its Consumer Health Business following the acquisition of Advangen Inc and subsequent growth in distribution of its FGF5 inhibitor hair growth products.

    The company’s Midkine Business has achieved development milestones with the completion of humanisation and lead antibody (CAB102) selection and the commencement manufacturing for clinical trials.

    It has commenced preparations for its ‘first in men’ clinical studies with reviewing clinical sites and negotiating with principal investigators.

     

 
watchlist Created with Sketch. Add AN1 (ASX) to my watchlist
(20min delay)
Last
1.4¢
Change
0.002(16.7%)
Mkt cap ! $5.868M
Open High Low Value Volume
1.3¢ 1.4¢ 1.3¢ $6.629K 500K

Buyers (Bids)

No. Vol. Price($)
2 1350000 1.2¢
 

Sellers (Offers)

Price($) Vol. No.
1.4¢ 489508 2
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
AN1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.